Clinical Trial Update: Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation [Phase 2]

View source ↗

Summary

Phase 2 trial of NP001 in patients with amyotrophic lateral sclerosis and systemic inflammation has completed, reporting safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• NP001

Snippet

Sponsor: Neuraltus Pharmaceuticals, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED